NewAmsterdam Pharma Co N.V. (NAMS) stock
NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
$19.74+0.35 (+1.81%)
Close on Nov 18, 2026Market cap $2.36BP/E –Yield –
NewAmsterdam Pharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
NewAmsterdam Pharma's revenue for the twelve months ending Jun 30, 2026 was $7.12M, down 88.9% year over year. For fiscal 2025 it was $22.50M, down 50.6% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.50M | -50.6% |
| FY2024 | Dec 31, 2024 | $45.56M | +223.4% |
| FY2023 | Dec 31, 2023 | $14.09M | -86.3% |
| FY2022 | Dec 31, 2022 | $102.69M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.70M | -80.7% |
| Q1 FY2026 | Mar 31, 2026 | $3.04M | +2.1% |
| Q4 FY2025 | Dec 31, 2025 | $32.00K | -99.7% |
| Q3 FY2025 | Sep 30, 2025 | $348.00K | -98.8% |
| Q2 FY2025 | Jun 30, 2025 | $19.15M | +740.1% |
| Q1 FY2025 | Mar 31, 2025 | $2.98M | +112.6% |
| Q4 FY2024 | Dec 31, 2024 | $12.77M | +1490.5% |
| Q3 FY2024 | Sep 30, 2024 | $29.11M | +889.8% |
| Q2 FY2024 | Jun 30, 2024 | $2.28M | +32.7% |
| Q1 FY2024 | Mar 31, 2024 | $1.40M | -83.8% |
| Q4 FY2023 | Dec 31, 2023 | $803.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $2.94M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.72M | – |
| Q1 FY2023 | Mar 31, 2023 | $8.63M | – |
See a number that looks wrong?